| Title |
Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
|
|---|---|
| Published in |
PLOS ONE, May 2013
|
| DOI | 10.1371/journal.pone.0063341 |
| Pubmed ID | |
| Authors |
Sumanta K. Pal, Rebecca A. Nelson, Nicholas Vogelzang |
| Abstract |
Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 32 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 19% |
| Researcher | 6 | 19% |
| Student > Postgraduate | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Doctoral Student | 3 | 9% |
| Other | 4 | 13% |
| Unknown | 5 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 53% |
| Agricultural and Biological Sciences | 2 | 6% |
| Veterinary Science and Veterinary Medicine | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Social Sciences | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 9 | 28% |